ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 821

Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update

Christina D Chambers1,2, Diana L Johnson1, Yunjun Luo1, Ronghui Xu2,3 and Kenneth L Jones1, 1University of California San Diego Department of Pediatrics, La Jolla, CA, 2University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, 3University of California San Diego Department of Mathematics, La Jolla, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Biologics, Outcome measures, pregnancy and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Epidemiology and Public Health I: Drug and Vaccine Safety

Session Type: Abstract Submissions (ACR)

Background/Purpose

Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA).

Methods

The OTIS Collaborative Research Group conducted a prospective cohort study in the U.S. and Canada between 2004 and 2013 comparing pregnancy outcomes in women with RA treated with adalimumab for some period of the first trimester to women with RA not treated with any adalimumab in pregnancy. No women in either group were also treated with methotrexate, but women may have been treated with another DMARD or steroid.  An additional comparison group included women without any autoimmune disease.  All three groups were recruited prior to 19 completed weeks’ gestation and followed by extensive telephone interviews throughout pregnancy and after birth. Medical records were reviewed, and a subset of live born infants received dysmorphological examination by a study physician (blinded to the mother’s status).  Outcomes were compared using logistic regression techniques and survival methods as appropriate with adjustment for confounders using propensity scoring if two or more confounders were identified.

Results

Seventy-four women exposed to adalimumab, 80 disease-matched comparison women, and 218 non-diseased women enrolled in the study. All women in the adalimumab-exposed group had at least one dose of the medication in the first trimester; approximately 43% of those women used the medication in all three trimesters.  The overall lost-to-follow up rate was 5.9%.  Disease severity, as measured by the HAQ at the time of enrollment and at 32 weeks’ gestation, was similar between the two disease-matched groups. The rate of major defects in the exposed, disease-matched, and non-diseased comparison groups was 5.6%, 7.8% and 5.5% respectively. In adjusted analysis, there was no significant difference in the overall rate of major malformations among live births in the adalimumab exposed vs. disease-matched group (adjusted Relative Risk (RR) 1.14, 95% Confidence Interval (CI) 0.26, 4.93).  A total of 234 infants (70% of live born infants) received the study-related physical examination. The proportion of children with 3 or more minor malformations in the three groups did not differ, and there was no specific pattern of minor malformations identified.  Using Cox Proportional Hazards modeling, the adjusted hazard ratio (HR) for spontaneous abortion was 1.96 (95% CI 0.47, 8.26) comparing the adalimumab vs. disease-matched groups; the rate was elevated in comparison to the non-diseased group (adjusted HR 3.79, 95% CI 1.01, 14.23), although the number of events was small. The rate of preterm delivery did not differ significantly among groups, nor did the proportion of infants who were small for gestational age.

Conclusion

Pregnant women with RA who are treated with adalimumab during the first trimester compared to women with the same underlying condition do not appear to be at increased risk of any of the adverse pregnancy outcomes evaluated. Although the sample size is small, these results provide reassuring data to women with RA who require treatment with adalimumab.


Disclosure:

C. D. Chambers,

AbbVie Inc.,

2,

Amgen,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Bristol-Myers Squibb,

2,

Genentech,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Parr Pharmaceutical,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Sandoz,

2,

Sanofi-Aventis Pharmaceutical,

2,

Teva Pharmaceuticals,

2,

UCB,

2;

D. L. Johnson,

AbbVie Inc.,

2,

Amgen,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Bristol-Myers Squibb,

2,

Genentech,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Parr Pharmaceutical,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Sanofi-Aventis Pharmaceutical,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

UCB,

2;

Y. Luo,

AbbVie Inc,

2,

Amgen,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Bristol-Myers Squibb,

2,

Genentech,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Parr Pharmaceutical,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Sandoz,

2,

Sanofi-Aventis Pharmaceutical,

2,

Teva Pharmaceuticals,

2,

UCB,

2;

R. Xu,

AbbVie Inc,

2,

Amgen,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Bristol-Myers Squibb,

2,

Genentech ,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Parr Phamaceutical,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Sandoz,

2,

Sanofi-Aventis Pharmaceutical,

2,

Teva Pharmaceuticals,

2,

UCB,

2;

K. L. Jones,

AbbVie Inc,

2,

Amgen,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Bristol-Myers Squibb,

2,

Genentech ,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Parr Pharmaceutical,

2,

Pfizer Inc,

2,

Roche Pharmaceuticals,

2,

Sandoz,

2,

Sanofi-Aventis Pharmaceutical,

2,

Teva Pharmaceuticals,

2,

UCB,

2.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcome-in-women-treated-with-adalimumab-for-the-treatment-of-rheumatoid-arthritis-an-update/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.